NPI 1427074285: Open Payments
NPI 1427074285. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,741 in 96 payments from 14 companies in 2025. Trend: 2023 $1,051 · 2024 $1,576 · 2025 $1,741
Food & beverage: $1,662Education: $80
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $247 |
| Otsuka America Pharmaceutical, Inc. | 12 | $231 |
| Teva Pharmaceuticals USA, Inc. | 11 | $226 |
| Axsome Therapeutics, Inc. | 12 | $221 |
| Almatica Pharma LLC | 9 | $149 |
| Janssen Pharmaceuticals, Inc | 7 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $118 |
| Alkermes, Inc. | 6 | $108 |
| Vanda Pharmaceuticals Inc. | 6 | $103 |
| Neurocrine BioSciences, Inc. | 4 | $65 |
Products named: REXULTI, CAPLYTA, Auvelity, LOREEV XR, AUSTEDO XR, SPRAVATO, TRINTELLIX, FANAPT.
